Mechanism-related Circumvention of Acquired ciVDiamminedichloroplatinum(II) Resistance Using Two Pairs of Human Ovarian Carcinoma Cell Lines by Ammine/ Amine Platinum(IV) Dicarboxylates

Cancer Research

Volumn 52, Issue 14, 1992, Pages 3857-3864

  Murrer, Barry A ^b   Mistry, Prakash ^a   Abel, George ^a   Loh, Swee Y ^a   O'Neill, Ciaran F ^a   Harrap, Kenneth R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEBISBUTYRATODICHLORO(CYCLOHEXYLAMINE)PLATINUM; BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; JM 244; MELPHALAN; METHOTREXATE; MITOMYCIN C; PLATINUM DERIVATIVE; PLATINUM IV AMINE DICHLORO CYCLOHEXYLAMINE DIBUTYRATE; PLATINUM IV AMINE DICHLORO PROPYLAMINE DIBENZOATE; TETRAPLATIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CROSS RESISTANCE; DNA ADDUCT; DNA CROSS LINKING; DRUG CONCENTRATION; DRUG RESISTANCE; DRUG TISSUE LEVEL; DRUG TOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA; DNA, NEOPLASM; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0026692952     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Loehrer, P. J., and Einhorn, L. H. Cisplatin. Ann. Intern. Med., 100: 704-713, 1984.
2. Ozols, R. F. Ovarian cancer: new clinical approaches. Cancer Treat. Rev., 18 (Suppl. A); 77-83, 1991.
3. Harrap, K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev., 12 (Suppl. A); 21-33, 1985.
4. Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., and Harrap, K. R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat. Rev., 12 (Suppl. A); 51-57, 1985.
5. Mangioni, C., Bolis, G., Pecorelli, S., Bragman, K., Epis, A., Favalli, G., Gambino, A., Landoni, F., Presti, M., Torri, W., Vassena, L., Lanaboni, F., and Marsoni, S. Randomised trial in ovarian cancer comparing cisplatin and carboplatin. J. Natl. Cancer Inst., 81: 1464-1468, 1989.
6. Gore, M. E., Fi7att, I., Wiltshaw, E., Dawson, T., Robinson, B. A., and Calvert, A. H. Cisplatin arboplatin cross-resistance in ovarian cancer. Br. J. Cancer, 60: 767-769, 1989.
7. Eisenhauer, E., Swerton, K., Sturgeon, J., Fine, S., O'Reilly, S., and Canetta, R. Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In: P. Bunn, R. Canetta, R. Ozols, and M. Rozencweig (eds.), Carboplatin: Current Perspectives and Future Directions, pp. 133-140. Philadelphia: W. B. Saunders Company, 1990.
8. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br. Med. J., 303: 884-893, 1991.
9. Roberts, J. J., Knox, R. J., Friedlos, F., and Lydall, D. A. DNA as the target for the cytotoxic and anti-tumour action of platinum co-ordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In: D. C. H. McBrien and T. F. Slater (eds.). Biochemical Mechanisms of Platinum Antitumour Drugs, pp. 29-64. Oxford: IRL Press, Ltd., 1986.
10. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterization of a ci5-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs. Cancer Res., 47: 414-418, 1987.
11. Andrews, P. A., Murphy, M. P., and Howell, S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res., 45: 6250-6253, 1985.
12. Hospers, G. A. P., de Vries, E. G. E., and Mulder, N. H. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line. Br. J. Cancer, 67: 79-82, 1990.
13. De Graeff, A., Slebos, R. J. C., and Rodenhuis, S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemo-ther. Pharmacol., 22: 325-332, 1988.
14. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (Cold Spring Harbor), 2: 35-43, 1990.
15. McKeage, M. J., Higgins, J. D., III, and Kelland, L. R. Platinum and other metal coordination compounds in cancer chemotherapy. Br. J. Cancer, 64: 788-792, 1991.
16. Burchenal, J. H., Irani, G., Kern, K., Lokys, L., and Turkevich, J. 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res., 74: 146-155, 1980.
17. Burchenal, J. H., Kalaher, K., OToole, T., and Chisholm, J. Lack of crossresistance between certain platinum coordination compounds in mouse leukemia. Cancer Res., 37: 2455-2457, 1977.
18. Goddard, P. M., Valenti, M. R., and Harrap, K. R. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Ann. Oncol., 2: 535-540, 1991.
19. Harrap, K. R., Jones, M., Siracky, J., Pollard, L., and Kelland, L. R. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol., J: 65-76, 1990.
20. Scher, H. I., Kelsen, D., Kalman, L., Jones, L., Burchenal, J., and Gralla, R. Phase II trial of l.,2-diaminocyclohexane(4-carboxyphthalato)platinum(II) (DACCP) in non small cell lung cancer. Cancer Chemother. Pharmacol., 72: 101-103, 1984.
21. Colombo, N., Sartori, E., Landoni, F., Favalli, G., Vassena, L., Zotti, L., Materman, E., Franks, C. R., Pecorelli, S., and Mangioni, C. Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancer. Cancer Treat. Rep., 70: 793-794, 1986.
22. Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25: 299-303, 1990.
23. Anderson, W. K., Quagliato, D. A., Haugwitz, R. D., Narayanan, V. L., and Wolpert-DeFilippes, M. K. Synthesis, physical properties and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat. Rep., 70: 997-1002, 1986.
24. Christian, M. C., Spriggs, D., Tutsch, K. D., O'Rourke, T., Von Hoff, D., Jacob, J. L., and Reed, E. Phase I trials with Ormaplatin (tetraplatin). In: S. B. Howell (ed.). Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy, pp. 453-458. New York: Plenum Press, 1991.
25. Hills, C. A., Kelland, L. R., Abel, G., Siracky, J., Wilson, A. P., and Harrap, K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59: 527-534, 1989.
26. Kelland, L. R., Jones, M., Abel, G., and Harrap, K. R. Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother. Pharmacol., 30: 43-50, 1992.
27. Harrap, K. R., Kelland, L. R., Jones, M., Goddard, P. M., Orr, R. M., Morgan, S. E., Murrer, B. A., Abrams, M. J., and Giandomenico, C. M. Platinum coordination complexes which circumvent cisplatin resistance. Adv. Enzyme Regul., 31: 31-43, 1991.
28. Harrap, K. R., Murrer, B. A., Giandomenico, C., Morgan, S. E., Kelland, L. R., Jones, M., Goddard, P. M., and Schurig, J. Ammine/amine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In: S. B. Howell (ed.). Platinum and Other Metal Coordi-nation Compounds in Cancer Chemotherapy, pp. 391-399. New York: Plenum Press, 1991.
29. Kelland, L. R., Murrer, B. A., Abel, G., Giandomenico, C. M., Mistry, P., and Harrap, K. R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cis-platin-resistant human ovarian cell lines. Cancer Res., 52: 822-828, 1992.
30. Kelland, L. R., Murrer, B. A., Abel, G., and Harrap, K. R. Structure-activity relationships in a series of novel platinum(II) and platinum(lV) ammine/ amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J. Cell. Pharmacol., 2: 225-234, 1991.
31. Mistry, P., Kelland, L. R., Abel, G., Sidhar, S., and Harrap, K. R. The relationships between glutathione, glutathione-5-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64: 215-220, 1991.
32. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
33. Griffiths, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinyl pyridine. Anal. Biochem., 106: 207-211, 1980.
34. Kirby, K. S., and Cook, E. A. Isolation of deoxyribonucleic acid from mammalian tissues. Biochem. J., 104: 254-251, 1967.
35. Burton, K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J., 62: 315-323, 1956.
36. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. C Friedberg and P. C. Hanawalt (eds.). Handbook of DNA Repair, pp. 379-401. New York: Marcel Dekker, Inc., 1981.
37. Roberts, J. J., and Friedlos, F. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol. Ther., 34: 215-246, 1987.
38. Hamer, D. H. Metallothionein. Annu. Rev. Biochem., 55:913-951, 1986.
39. Hospers, G. A. P., Mulder, N. H., de Jong, B., de Ley, L., Uges, D. R. A., Fichtinger-Schepman, A. M. J., Scheper, R. J., and de Vries, E. G. E. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res., 48: 6803-6807, 1988.
40. Fram, R. J., Woda, B. A., Wilson, J. M., and Robichaud, N. Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells. Cancer Res., 50: 72-77, 1990.
41. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC), 241: 1813-1815, 1988.
42. Bungo, M., Fujiwara, Y., Kasahara, K., Nakagawa, K., Ohe, Y., Sasaki, Y., Irino, S., and Saijo, N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res., 50:2549-2553, 1990.
43. Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D., and Frei, E., III. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 47: 388-393, 1987.
44. Andrews, P. A., Velury, S., Mann, S. C., and Howell, S. B. cis-Diam-minedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48:68-73, 1988.
45. Kraker, A. J., and Moore, C. W. Accumulation of cis-diamminedichloroplat-inum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res., 48:9-13, 1988.
46. Kawai, K., Kamatani, N., Georges, E., and Ling, V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265:13137-13142,1990.
47. Bernal, S. D., Speak, J. A., Boeheim, K., Dreyfuss, A. I., Wright, J. E., Teicher, B. A., Rosowsky, A., Tsao, S. W., and Wong, Y. C. Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and ci5-platinum. Mol. Cell. Biochem., 95:61-70, 1990.
48. Kikuchi, Y., Iwano, I., Miyauchi, M., Sasa, H., Nagata, I., and Kuki, E. Restorative effects of calmodulin antagonists on reduced cisplatin upUke by cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol., 39:199-203, 1990.
49. Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to ci5-diamminedichloroplatinum(II). Biochemistry, 27: 4730-4734, 1988.
50. Masuda, H., Ozols, R. F., Lai, G-M., Fojo, A., Rothenberg, M., and Hamilton, T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res., 48: 5713-5716, 1988.
51. Kelland, L. R., Mistry, P., Abel, G., Friedlos, F., Loh, S. Y., Roberts, J. J., and Harrap, K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res., 52: 1710-1716, 1992.
52. Murphy, D., McGown, A. T., Crowther, D., Mander, A., and Fox, B. W. Metallothionein levels in ovarian tumours before and after chemotherapy. Br. J. Cancer, 63: 711-714, 1991.